SMTL ID : 6n6o.1

Crystal structure of the human TTK in complex with an inhibitor

Coordinates

PDB Format

Method

X-RAY DIFFRACTION 2.60 Å

Oligo State

monomer

Ligands

1 x KE7: 4-({5-chloro-4-[(cis-4-hydroxy-4-methylcyclohexyl)oxy]-7H-pyrrolo[2,3-d]pyrimidin-2-yl}amino)-N,N-dimethyl-3-{[(2R)-1,1,1-trifluoropropan-2-yl]oxy}benzamide(Non-covalent)

KE7.1: 15 residues within 4Å: Chain A: K.17, I.19, V.27, Q.29, A.39, M.90, E.91, C.92, G.93, N.94, I.95, D.96, S.99, L.142 Ligands: 1PE.2 5 PLIP interactions: 5 interactions with chain A Hydrophobic interactions: A:V.27, A:L.142, A:L.142 Hydrogen bonds: A:G.93, A:G.93

1 x 1PE: PENTAETHYLENE GLYCOL(Non-functional Binders)

1PE.2: 8 residues within 4Å: Chain A: K.41, V.43, Y.56, E.59, M.88, I.151, A.156 Ligands: KE7.1 1 PLIP interactions: 1 interactions with chain A Hydrogen bonds: A:K.41

1 x EDO: 1,2-ETHANEDIOL(Non-functional Binders)

EDO.3: 6 residues within 4Å: Chain A: K.202, K.265, Q.266, R.267, I.268, E.272 3 PLIP interactions: 3 interactions with chain A Hydrogen bonds: A:K.202, A:S.269, A:E.272

Links

RCSB   PDBe   PDBe-KB   PDBj   PDBsum   CATH   PLIP

Citation

Riggs, J.R. et al., Design and Optimization Leading to an Orally Active TTK Protein Kinase Inhibitor with Robust Single Agent Efficacy. J.Med.Chem. (2019)

Release Date

2019-05-15

Peptides

Dual specificity protein kinase TTK: A

SMTL:PDB

SMTL Chain Id:
PDB Chain Id:

A
A

Dual specificity protein kinase TTK